ADVANCING IMMUNOPEPTIDOMICS: LEVERAGING EVOSEP ONE FOR HIGH-THROUGHPUT ANALYSIS AND DISCOVERY

Immunopeptidomics is a field that combines proteomics and immunology to study the complex repertoire of peptides presented by major histocompatibility complex (MHC) molecules on the cell surface.

These MHC-bound peptides, known as immunopeptidomes, play crucial roles in immune recognition and activation, influencing various physiological and pathological processes such as immune surveillance, infectious diseases, autoimmunity, and cancer.

Join our webinar to explore recent advancements, challenges, and applications in immunopeptidomics. Discover how EvosepOne accelerates discoveries, and support the understanding of immune responses and diseases.

IMMUNOPEPTIDOMICS ON THE EVOSEP ONE – NEW LEVELS OF SAMPLE THROUGHPUT AND PRODUCTIVITY

Immunopeptidomics is the study of peptide antigens that are bound to and presented on the cell surface by molecules encoded by the Major Histocompatibility, a highly polymorphic region of the genome that encode molecules involved in immune responses. These peptides are derived from both intracellular and extracellular degradation of the parental proteins, generating a highly complex repertoire of peptide ligands, including peptides derived from pathogens, tissue specific and cancer specific antigens when relevant. In humans, human leukocyte antigen (HLA) class I and class II molecules are of particular interest for immunopeptidomic analysis. These molecules are encoded by several loci and constitute thousands different alleles that vary between individuals. Thus, immunopeptidomes are highly individualized and almost impossible to accurately predict. This predicates the empirical measurement of the complexity and diversity of immunopeptidomes using mass spectrometry. Due to the relatively small amounts of material available for analysis the use of nanoflow LC-MS for immunopeptidome analysis is critical. Here I explore the implementation of the high throughput EvoSEP one platform couples to a Bruker timsTOF Pro 2 for robust analysis of immunopeptidomes across a variety of tissues and cell lines. Using the Whisper 20SPD method data quality and depth is maintained whilst sample carryover is negligible allowing more productive use of instrument time; I highlight significant improvements in throughput with over 1500 immunopeptidomes characterised in just 3 months.

Presenter: Anthony Purcell (Professor, Purcel Lab, Monsah University)

Presenter: Nicolai Bache (Head of Applications at Evosep)

MAPPS: High throughput immunopeptidomics for the assessment of the immunogenic potential of protein biotherapeutics

Biologics, mostly monoclonal antibodies and recombinant proteins, are a class of drugs used to treat some particularly difficult conditions. These proteins, when recognized as non-self by the immune system, can elicit unwanted immunogenicity. One of the first steps in this cascade is the presentation of fragments of this protein by MHC complexes on antigen presenting cells, which might ultimately lead to generation of anti-drug antibodies (ADAs). These ADAs can lower the therapeutic efficiency and can lead to severe immunogenic effects. To bring safe biotherapeutics to the market it is critical to thoroughly assess the immunogenic profile of a biotherapeutic. MAPPS (MHC associated peptides proteomics) assays are the method of choice to define all potential immunogenic regions of a protein. ImmuneSpec, an advanced immunopeptidomics platform, offers MAPPS as a service. Here we show how the combination of high-throughput MHC peptide purification, fast LC using EvoSep, and high sensitive MS addresses these needs.

Presenter: Kurt Boonen (Assistant Professor, Deparment of biomedical sciences, University of Antwerp)

Presenter: Nicolai Bache (Head of Applications at Evosep)